LOXO-292
- CAS No.
- 2152628-33-4
- Chemical Name:
- LOXO-292
- Synonyms
- SELPERCATINIB;LOX-292;CPD2206;LOX0292;Orapani;LOXO-292;ARRY-192);Serpatinib;LOXO-292 USP/EP/BP;Inhibitor LOXO-292
- CBNumber:
- CB34805442
- Molecular Formula:
- C29H31N7O3
- Molecular Weight:
- 525.6
- MOL File:
- 2152628-33-4.mol
- Modify Date:
- 2024/7/24 13:33:21
| Density | 1.36±0.1 g/cm3(Predicted) |
|---|---|
| storage temp. | Store at -20°C |
| solubility | DMSO:20.0(Max Conc. mg/mL);38.05(Max Conc. mM) |
| form | A crystalline solid |
| pka | 14.00±0.29(Predicted) |
| color | White to off-white |
| InChIKey | XIIOFHFUYBLOLW-UHFFFAOYSA-N |
| SMILES | C12=C(C#N)C=NN1C=C(OCC(O)(C)C)C=C2C1=CC=C(N2CC3CC(N3CC3=CC=C(OC)N=C3)C2)N=C1 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P280-P301+P312-P302+P352-P305+P351+P338 |
LOXO-292 Chemical Properties,Uses,Production
Uses
Selpercatinib is a highly selective, potent RET inhibitor, an oral drug used to treat cancers in people whose tumours have been altered (mutated or fused) in specific genes (RET stands for "rearrangement during transfection").
brand name
Retevmo
General Description
Class: receptor tyrosine kinase; Treatment: RET-altered lung/thyroid cancers; Other name: ARRY-192, LOXO-292; Oral bioavailability = 73%; Elimination half-life = 32 h; Protein binding = 97%
Side effects
Selpercatinib can cause serious side effects including liver toxicity, high blood pressure, heart rhythm changes due to prolongation of heart electrical activity (QT prolongation), bleeding, allergic reactions, impaired wound healing and harm to an unborn baby.
Selpercatinib may cause harm to a developing fetus or a newborn baby.
target
RET
Dosage
The recommended selpercatinib dose based on body weight is:
(1) Less than 50 kg: 120 mg orally twice daily
(2) 50 kg or greater: 160 mg orally twice daily
LOXO-292 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| Zison Pharmaceutical (Shandong) Co., Ltd. | +86-0086-531-88259693 +86-18660188356 | China | 57 | 58 | Inquiry |
| Jinan Million Pharmaceutical Co., Ltd | 0531-68659554 +8613031714605 | China | 192 | 58 | Inquiry |
| BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | +86-18600796368 +86-18600796368 | China | 123 | 58 | Inquiry |
| Hebei Weimiao Import and Export Trade Co., Ltd. | +undefined19948166995 | China | 73 | 58 | Inquiry |
| Sigma Audley | +86-18336680971 +86-18126314766 | China | 491 | 58 | Inquiry |
| hebei hongtan Biotechnology Co., Ltd | +86-86-1913198-3935 +8617331935328 | China | 973 | 58 | Inquiry |
| Hebei Saisier Technology Co., LTD | +86-18400010335 +86-18034520335 | China | 996 | 58 | Inquiry |
| Apeloa production Co.,Limited | +8619933239880 | China | 853 | 58 | Inquiry |
| Hebei Longbang Technology Co., LTD | +86-18032476855 +86-18032476855 | China | 941 | 58 | Inquiry |
Related articles
- LOXO-292: A Promising RET Inhibitor with Strong Anti-Tumor Effects and Manageable Adverse Events
- LOXO-292 inhibits RET-pathway, demonstrating anti-tumor effects and dose-proportional pharmacokinetics. Common adverse events ....
- Mar 4，2024
- Selpercatinib: Synthesis and Description
- Selpercatinib (LOXO-292) is synthesised using sulfonyl chloride as a raw material by chemical reaction.
- Jan 5，2024
- LOXO-292: Bioactivity and Chemicaland toxicological studies
- LOXO-292 is a selective and potent RET inhibitor,it is a novel broad-spectrum anticancer?drug with the targeted?function for R....
- Dec 20，2022